Abstract
Despite the considerable effort made in the past decades, multiple aspects of cancer management remain a challenge for the scientific community. The severe toxicity and poor bioavailability of conventional chemotherapeutics, and the multidrug resistance have turned the attention of researchers towards the quest of drug carriers engineered to offer an efficient, localized, temporized, and doze-controlled delivery of antitumor agents of proven clinical value. Molecular imprinting of chemotherapeutics is very appealing in the design of drug delivery systems since the specific and selective binding sites created within the polymeric matrix turn these complex structures into value-added carriers with tunable features, notably high loading capacity, and a good control of payload release. Our work aims to summarize the present state-of-the art of molecularly imprinted polymer-based drug delivery systems developed for anticancer therapy, with emphasis on the particularities of the chemotherapeutics’ release and with a critical assessment of the current challenges and future perspectives of these unique drug carriers.
Highlights
Inorganic Chemistry Dept., Faculty of Pharmacy, “Iuliu Haţieganu” University of Medicine and Pharmacy, Analytical Chemistry Dept., Faculty of Pharmacy, “Iuliu Haţieganu” University of Medicine and Pharmacy, These authors contributed to this work
After 90 min only a 10% reduction of the cell viability was induced by the MIP-drug delivery systems (DDS), in the presence of alternative magnetic field (AMF), cell viability decreased to 60% due to the accelerated DOX release, without any significant temperature elevation of the medium
Conventional primary or adjuvant chemotherapy is associated with high non-specific toxicity and severe side-effects, due to the poor pharmacodynamic selectivity and unfavorable pharmacokinetic profile of the current anticancer drugs
Summary
Despite the substantial development in early detection and treatment of cancer, malignancies continue to represent the second worldwide cause of death, outranked only by cardiovascular diseases. The indiscriminate normaldrugs andwithin cancer cellsdrug duedelivery to thesystems non-specific drug distribution in the Thetoxicity loading ofto anticancer different (DDS) plays a significant roleadministrated in improving treatment ways, by an improvement of the body limits the doses,efficiency which through in turnmultiple may lead tomainly negligible effects on the ultimate target. DDS must be capablewith of intelligently releasing theirpharmaceutical cargo as a response formulations to the local at predictable of maintaining drug concentration for theof required amount addressed asenvironment, they are listed amongrates, theand main causes ofthethe drastic decrease the therapeutic value of of time [8] These carriers may provide means to improve drug solubility A critical evaluation is performed on why the current research exploiting this particular application of these smart materials delivering chemotherapeutics seems to be stuck in early stages of design and why their translation into preclinical/clinical studies is lingering
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
